Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects

Por Kollmannsberger, C, Soulieres, D, Wong, R, Scalera, A, Gaspo, R, Bjarnason, G
Publicado em 2007

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

Por Larochelle, P., Kollmannsberger, C., Feldman, R.D., Schiffrin, E.L., Poirier, L., Patenaude, F., Ruether, D., Myers, M., Bjarnason, G.
Publicado em 2012

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis

Por White, N M A, Masui, O, Newsted, D, Scorilas, A, Romaschin, A D, Bjarnason, G A, Siu, K W M, Yousef, G M
Publicado em 2014

Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis

Por White, N M A, Masui, O, Newsted, D, Scorilas, A, Romaschin, A D, Bjarnason, G A, Siu, K W M, Yousef, G M
Publicado no Br J Cancer (2017)

Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting

Por Nazha, S., Tanguay, S., Kapoor, A., Jewett, M., Kollmannsberger, C., Wood, L., Bjarnason, G., Heng, D., Soulières, D., Reaume, N., Basappa, N., Lévesque, E., Dragomir, A.
Publicado no Curr Oncol (2018)

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group

Por Maroun, J., Kocha, W., Kvols, L., Bjarnason, G., Chen, E., Germond, C., Hanna, S., Poitras, P., Rayson, D., Reid, R., Rivera, J., Roy, A., Shah, A., Sideris, L., Siu, L., Wong, R.
Publicado em 2006

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Por Heng, D. Y., MacKenzie, M. J., Vaishampayan, U. N., Bjarnason, G. A., Knox, J. J., Tan, M. H., Wood, L., Wang, Y., Kollmannsberger, C., North, S., Donskov, F., Rini, B. I., Choueiri, T. K.
Publicado em 2012

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215

Por White, N M A, Khella, H W Z, Grigull, J, Adzovic, S, Youssef, Y M, Honey, R J, Stewart, R, Pace, K T, Bjarnason, G A, Jewett, M A S, Evans, A J, Gabril, M, Yousef, G M
Publicado em 2011

Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials

Por Heng, D. Y. C., Choueiri, T. K., Rini, B. I., Lee, J., Yuasa, T., Pal, S. K., Srinivas, S., Bjarnason, G. A., Knox, J. J., MacKenzie, M., Vaishampayan, U. N., Tan, M. H., Rha, S. Y., Donskov, F., Agarwal, N., Kollmannsberger, C., North, S., Wood, L. A.
Publicado em 2014

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Por Hotte, S.J., Bjarnason, G.A., Heng, D.Y.C., Jewett, M.A.S., Kapoor, A., Kollmannsberger, C., Maroun, J., Mayhew, L.A., North, S., Reaume, M.N., Ruether, J.D., Soulieres, D., Venner, P.M., Winquist, E.W., Wood, L., Yong, J.H.E., Saad, F.
Publicado em 2011

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

Por Jonker, D J, Karapetis, C S, Harbison, C, O'Callaghan, C J, Tu, D, Simes, R J, Malone, D P, Langer, C, Tebbutt, N, Price, T J, Shapiro, J, Siu, L L, Wong, R P W, Bjarnason, G, Moore, M J, Zalcberg, J R, Khambata-Ford, S
Publicado em 2014

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

Por Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R
Publicado no Br J Cancer (2015)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Por Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Publicado em 2014

Management of Kidney Cancer: Canadian Kidney Cancer Forum Consensus Update 2011: Canadian Kidney Cancer Forum 2011

Por Jewett, MAS, Finelli, A, Kollmannsberger, C, Wood, L, Legere, L, Basiuk, J, Canil, C, Heng, D, Reaume, N, Tanguay, S, Atkins, M, Bjarnason, G, Dancey, J, Evans, M, Fleshner, N, Haider, M, Kapoor, A, Uzzo, R, Maskens, D, Soulieres, D, Yousef, G, Basappa, N, Bendali, N, Black, P, Blais, N, Cagiannos, I, Care, M, Chow, R, Chung, H, Czaykowski, P, DeRosa, D, Durrant, K, Ellard, S, Farquharson, G, Filion-Brulotte, C, Gingerich, J, Godbout, L, Grant, R, Hamilton, W, Kassouf, W, Kurban, G, Lane, K, Lattouf, JB, Lau, D, Leveridge, M, McCarthy, J, Moore, R, North, S, O’Brien, P, Pituskin, E, Racine, P, Rendon, R, So, A, Sridhar, S, Stubbs, K, Su, Z, Taylor, L, Udall, T, Venner, P, Vogel, W, Yap, S, Yau, P, Cooper, M, Giroux, N, Miron, D, Mosher, D, Ross, K, Willacy, J
Publicado em 2012